UK Markets closed

Ironwood Pharmaceuticals, Inc. (IRWD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.64+0.15 (+1.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.49
Open9.54
Bid8.57 x 1000
Ask10.90 x 3000
Day's range9.26 - 9.67
52-week range7.99 - 14.10
Volume1,802,700
Avg. volume1,993,871
Market cap1.542B
Beta (5Y monthly)1.43
PE ratio (TTM)15.67
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press releases
  • Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call
    Business Wire

    Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 5, 2020. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 2794527. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
    Business Wire

    Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that data from IW-3718-302, one of Ironwood’s two identical Phase III trials evaluating IW-3718 in refractory gastroesophageal reflux disease (GERD), did not meet the pre-specified criteria associated with a planned early efficacy assessment. Following the assessment from an independent data monitoring committee, Ironwood unblinded the data and confirmed that IW-3718-302 did not meet the criteria, including the study’s primary endpoint of achieving a statistically significant improvement in heartburn severity. IW-3718 was generally well-tolerated in study IW-3718-302.

  • Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
    Business Wire

    Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: